Abstract Library

#3471 A novel in vitro spheroid model enables multi-modality assessment of the anti-tumoral immune response in pancreatic neuroendocrine neoplasms

Introduction: Patients harbouring pancreatic neuroendocrine neoplasms (PNENs) often present as a non-resectable disease due to distant metastases, hence, efficacy of the current medical intervention is limited. Activation of the mammalian target of rapamycin (mTOR) pathway is a known tumorigenic driver in PNENs. mTOR inhibition by Everolimus (EVE) delays PNEN progression, but the mechanism is not clear. EVE is also used as an immunosuppressant, thus we hypothesized that it may suppress the anti-tumoral immune response.

Conference:

Presenting Author:

Authors: Nasirov S, Zaig E, Mor-Cohen R, Telerman A, Tirosh A,

Keywords: PNEN, spheroid, Everolimus, mTOR,

#3188 mTOR pathway inhibitors differently effect proliferation and gene expression in pancreatic and pulmonary NET cell lines

Introduction: The mammalian target of rapamycin (mTOR) is part of the PI3K/Akt/mTOR signalling pathway which has a central role in the oncogenesis of neuroendocrine tumors (NETs). Everolimus (EVE), an mTOR inhibitor, has shown effective in delaying progression of advanced NETs, but with a limited long-term efficacy, possibly due to a compensatory activation of the PI3K/AKT signalling. BYL719, a PI3K inhibitor, was shown to inhibit growth of several NET cell line models.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Mor-Cohen R

Authors: Mor-Cohen R, Braiman N, Tirosh A,

Keywords: NET cell lines, PI3K/Akt/mTOR signalling, Wnt signalling, everolimus, BYL719,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,

#1320 Are eIFs Ingredients for Neuroendocrine Tumorigenesis?

Introduction: Neuroendocrine tumors (NETs) develop in almost any organ, therefore they are a very heterogeneous group of tumors. One of the major activities in every cell is the translation of mRNA to the corresponding protein, which plays an important role in cancer development. Crucial for this translation process are eukaryotic initiation factors (eIFs), which are themselves regulated by the mammalian target of Rapamycin (mTOR)-pathway. Mutation or deregulated expression of eIFs influences cell growth and proliferation, contributing to carcinogenesis. The incidence of NETs has increased fivefold over the last three decades.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Haybaeck J

Authors: Gantenbein N, Smolle E, Thalhammer M, Kornprat P, Lackner C,

Keywords: NETs, mTOR, eukaryotic translation initiation,

#1307 Expression of m-TOR Pathway Components in Gastric Neuroendocrine Neoplasms: A Pilot Study

Introduction: The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in the regulation of cell proliferation, protein synthesis and neuroendocrine tumor growth.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Delektorskaya V, Peregorodiev I, Bokhian V, Stilidi I,

Keywords: neuroendocrine, neoplasm, gastric, immunohistochemistry ,